Observational Study

Metabolite profile comparisons between ascending and descending colon tissue in healthy adults

Bridget A Baxter, Kristopher D Parker, Michael J Nosler, Sangeeta Rao, Rebecca Craig, Catherine Seiler, Elizabeth P Ryan

ORCID number: Bridget A Baxter (0000-0001-9549-1989); Kristopher D Parker (0000-0002-6872-1547); Michael J Nosler (0000-0001-9174-0538); Sangeeta Rao (0000-0002-9234-0082); Rebecca Craig (0000-0001-6503-746X); Catherine Seiler (0000-0001-8357-818X); Elizabeth P Ryan (0000-0002-1577-0919).

Author contributions: Ryan EP and Nosler MJ designed research and maintained study oversight; Nosler MJ, Craig R and Seiler C conducted human tissue sample collections; Baxter BA and Parker KD analyzed the metabolite profile and microbiome data collected from stool and colon; Parker KD and Rao S performed statistical analysis; Baxter BA, Parker KD, and Ryan EP wrote the manuscript; Ryan EP had primary responsibility and all authors approved the final product.

Supported by the CancerCure Foundation and the University of Colorado Cancer Center Support Grant, Division of Cancer Control and Prevention (Aurora, CO), No. P30CA06934.

Institutional review board statement: Colorado State University Institutional Review Board No. 15-6051, and University Colorado Health-North Institutional Review Board No. 0010144.

Informed consent statement: Participants provided written informed consent.

Bridget A Baxter, Kristopher D Parker, Elizabeth P Ryan, Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Fort Collins, CO 80523, United States

Michael J Nosler, University of Colorado Health Gastroenterology Clinic, Fort Collins, CO 80524, United States

Sangeeta Rao, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, United States

Rebecca Craig, Harmony Surgery Center, Fort Collins, CO 80528, United States

Catherine Seiler, Director of Clinical Operations, Harmony Surgery Center, Fort Collins, CO 80523, United States

Corresponding author: Elizabeth P Ryan, PhD, Associate Professor, Department of Environmental and Radiological Health Sciences, Colorado State University, 1617 Campus Delivery, Fort Collins, CO 80523, United States. e.p.ryan@colostate.edu

Abstract

BACKGROUND
Obesity is a risk factor for colorectal cancer, yet metabolic distinctions between healthy right and left colon tissue, before cancer is diagnosed, remains largely unknown. This study compared right-ascending and left-descending colon tissue metabolomes to identify differences from the stool metabolome in normal weight, overweight, and obese adults.

AIM
To examine right and left colon tissue metabolites according to body mass index that may serve as mechanistic targets for interventions and biomarkers for colon cancer risk.

METHODS
Global, non-targeted metabolomics was applied to assess right-ascending and left-descending colon tissue collected from healthy adults undergoing screening colonoscopies to test the hypothesis that BMI differentially impacts colon tissue metabolite profiles. The colon tissue and stool metabolome of healthy adults (n = 24) was analyzed for metabolite signatures and metabolic pathway networks implicated in progression of colorectal cancer.
INTRODUCTION

Body mass index (BMI) of 30% or greater is an established risk factor for colon cancer in men and women[3,4]. Obesity is a complex lipid-storage disease with metabolic aberrations locally in the gut and systemically in the host that increase risk for multiple chronic diseases[5]. Similar relationships occur for obesity and the incidence of larger (vs smaller) colon adenomas[6,7]. Weight gain from early to middle adulthood increases risk[8], whereby middle-aged obese adults had a 60% increase risk of right-side colon cancer compared to the left-side[9]. We and others have previously shown that stool reveals changes in microbial communities[10], and modulation by diet[11], yet this may not accurately reflect metabolic differences between the right and left side colon tissue[12].

Right-cancer patients have a worse prognosis with a median survival of 76.6 mo while left-sided have median survival of 101 mo[13] and right-sided tumors are significantly larger in size with a higher tumor grade when compared to left side colon cancer[14,15]. African American and non-Hispanic blacks have 24% greater odds of right-sided colon cancer[16]. Physical inactivity, excess body weight, alcohol, smoking, and a central deposition of adiposity are consistent risk factors for colorectal cancer.
High consumption of red meat more than 3 times/wk has been associated with 2-fold increased risk for colon cancer and these food components merit attention in the tissue of healthy adults[14].

Metabolomics is a high-throughput screening methodology that is sensitive for detection of exogenous and endogenous (microbial, host and food) products of metabolism[15] and can aid in identification of disease risk biomarkers[16]. Metabolite profiling analysis of ascending and descending colon tissue was conducted herein to assess metabolic differences between colon locations that differ from stool. This study utilized normal weight, overweight and obese adults for investigation of colonic compounds that may impact colon cancer risk[17]. Metataxonomics of colon tissue by location has varied results[18,19] and provided rationale for using metabolomics. The major objective of this study was to identify metabolic pathways that distinguished ascending and descending colon tissue and to reveal metabolites altered by overweight and obesity that may pose elevated risks for developing cancer. We hypothesized that lipids (e.g., fatty acids, bile acids, phospholipids, monoacylglycerol, and endocannabinoids) are distinct in type and abundance between the ascending and descending colon, and that colon tissue metabolomes will differ according to BMI when compared to stool in overweight and obese adults.

**MATERIALS AND METHODS**

**Study design- participant recruitment**

Ninety-three healthy adults were contacted prior to a scheduled colonoscopy in Fort Collins CO. Forty adult males and females provided written informed consent to collect a stool sample and an ascending and descending colon tissue biopsy. Twenty-four individuals (colon and stool) were assessed for non-targeted metabolomics. Eligible participants were provided a stool kit and study instructions. The gastroenterology clinical nurses and research staff confirmed study code number assignments and ensured the completed de-identification at the site of colonoscopy procedure. Colorado State University study personnel were contacted by clinic staff for sample retrieval immediately following procedure. Three study groups were BMI 20-24.9 for normal weight (n = 9), BMI 25-29.9 for overweight (n = 9) and BMI 30+ for obese (n = 6) adults. One normal weight female (BMI 24) had the right and left colon and stool sample applied for metataxonomic analysis (16S rRNA gene sequencing). Participant’s inclusion criteria for this study were at least 18 years of age, a scheduled routine colonoscopy, no prior history of colorectal cancer diagnosis, non-smoker, and not having taken antibiotics for at least one month prior to the standard of care, routine screening colonoscopy.

The colon tissue collected for this study was visually determined by the gastroenterologist performing the procedure to be normal, healthy tissue without polyps. Each participant had an about 5 mm biopsy of ascending (right) and descending (left) colon tissue and a self-collected stool sample prior to bowel preparation. Colonoscopy was completed by Centers for Gastroenterology-Fort Collins and University of Colorado-Health North Gastroenterology Clinic (Fort Collins, CO, United States). Samples were de-identified for personal information and study ID coded before storage and metabolite processing at Colorado State University. The number of polyps removed by the doctor with the respective location was provided following the procedure. This study received IRB approval, and include protocol number; Colorado State University IRB No. 15-6051, and University of Colorado Health IRB No. 0010144. Participants in this study had no history of diseases related to the liver or biliary tract and they did not have previous procedures such as cholecystectomy or ileal resections. This study did not collect information regarding the family history of colorectal cancer and did not perform hereditary genetic or epigenetic screening history on the patients. Table 1 shows the study participant characteristics.

**Colon tissue and stool sample collection**

Stool samples were self-collected by participants in a pre-labeled study coded container and frozen at -80 °C. Approximately 5 mm of normal healthy colon tissue were stored immediately at -80 °C following collection. Samples were shipped on dry ice to Metabolon, Inc. (Durham, NC, United States) and a single participant sample underwent DNA extraction for metataxonomics.

**Sample accessioning and preparation**

Tissue and stool metabolite extraction was completed using 80% methanol as previously described[20], prior to ultrahigh performance liquid chromatography-
Table 1  Characteristics of the study participants (n = 24)

| Characteristics                        | Total (n = 24) | Normal (n = 9) | Overweight (n = 9) | Obese (n = 6) |
|----------------------------------------|---------------|---------------|-------------------|--------------|
| Sex                                    |               |               |                   |              |
| Males                                  | 5             | 0             | 4                 | 1            |
| Females                                | 19            | 9             | 5                 | 5            |
| BMI (mean ± SD, kg/m²)                 | 27.6 ± 5.8    | 22 ± 1        | 26.7 ± 1.3        | 35 ± 5       |
| Total number of people with polyps removes | 14          | 6             | 4                 | 4            |
| Total number polyps removed            | -             | 14            | 13                | 22           |
| Polyp Location                         |               |               |                   |              |
| Cecum                                  | -             | 1             | 0                 | 3            |
| Ascending                               | -             | 6             | 2                 | 10           |
| Transverse                             | 2             | 1             | 1                 |              |
| Sigmoid                                | -             | 2             | 4                 | 6            |
| Rectum                                 | -             | 0             | 6                 | 0            |
| Descending                              | -             | 3             | 0                 | 2            |
| History of hypertension                |               |               |                   |              |
| Yes                                    | 6             | 2             | 3                 | 2            |
| No                                     | 18            | 7             | 6                 | 4            |
| History of type 2 diabetes             |               |               |                   |              |
| Yes                                    | 3             | 0             | 2                 | 1            |
| No                                     | 21            | 9             | 7                 | 5            |
| Taking dietary supplements             |               |               |                   |              |
| Yes                                    | 14            | 4             | 8                 | 2            |
| No                                     | 10            | 5             | 1                 | 4            |
| Smoking history                        |               |               |                   |              |
| Past smoker                            | 9             | 2             | 6                 | 1            |
| Never                                  | 15            | 6             | 4                 | 5            |

No participants had cancer detected from the screening exam. BMI: Body mass index.

tandem mass spectroscopy (UPLC-MS/MS) as completed by Metabolon, Inc. Positive and negative ion modes were chosen to provide broad, non-targeted detection of metabolites.

Samples were extracted using the automated MicroLab STAR® system from Hamilton Company. A set of recovery standards were added prior to the first step in the extraction process for quality control purposes. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. Samples were placed briefly on a TurboVap® (Zymark) to remove the organic solvent. The sample extracts were stored overnight under nitrogen before preparation for analysis.

**UPLC-MS/MS analysis**
The UPLC-MS/MS portion of the platform was based on a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35000 mass resolution. The protocol has been previously described by our lab[7].

**Data extraction and compound identification**
Raw data were extracted, peak-identified, and processed using Metabolon’s hardware and software. Compounds were identified by comparison to library entries of purified standards or recurrent unknown entities as previously described[7].

**Statistical analysis**
Healthy colon tissue or stool metabolite profiles were semi-quantified in terms of relative abundance and median scaled to 1. Fold differences were calculated for normal weight, overweight and obese (colon tissue and stool) and for colon tissue between ascending and descending sites. A matched-pairs 2-way ANOVA was completed using the scaled relative abundance of each metabolite, experimental groups in ArrayStudio on log transformed data, were used for normal weight, overweight and obese. Metabolite profile distinctions between ascending and descending colon tissue were evaluated using \( P < 0.05 \) for statistical significance with matched pair \( t \)-test. An estimate of the false discovery rate (Q value) was calculated to account the multiple comparisons across metabolites that are typical of metabolomics-based studies with a Q value \( \geq 0.01 \). A linear regression analyses for colon metabolites were preformed to compare the groups with polyp removal to no polyp removal, after adjusting for the effect of weight category of the subjects.

Principal component analysis and hierarchical clustering were applied to understand the similarities and differences between samples and/or groups of samples in a complex dataset. Unsupervised clustering was performed using the ward D2 method[18]. Random forest (RF) analysis, a supervised classification technique, was applied for identifying candidate biomarkers. To determine which variables (biochemicals) make the largest contribution to the classification of BMI, a “variable importance” measure was computed. We used the “Mean Decrease Accuracy” as this metric prediction accuracy[21].

**Metataxonomics: Sample handling and DNA extraction, sequence read processing, and feature table analyses**

DNA was extracted from colon tissue and stool with the MoBio PowerSoil Kit according to manufacturer protocols. Amplification of the V4 region of the 16S rRNA gene and amplicon sequencing followed the standards outlined by the Earth Microbiome Project. Raw FASTQ-formatted forward reads were imported into the Quantitative Insights Into Microbial Ecology 2 (QIIME 2) platform[22]. A feature table comprised of amplicon sequence variants (ASVs) was inferred from reads using the DADA2 algorithm[23]. Taxonomy was assigned to each representative ASV sequence using Naïve Bayes classifiers trained against 99% OTU reference collections from Greengenes 13_8 or SILVA 132. The raw feature table, representative sequences, and taxonomy tables were exported from QIIME 2 for further processing using R[24]. Following import, a master table comprised of ASV IDs with corresponding representative sequences, full and truncated Green-genes and SILVA taxonomic lineages, and absolute abundances for all ASVs within each sample was constructed. This master table served as the entry point for all downstream processing and analysis. Comparisons of microbiota composition proceeded from the compositional data analysis paradigm with count zero multiplicative replacement prior to applying the centred log-ratio (clr) transformation[25]. Taxon abundance are depicted as proportions (i.e., relative abundances). Supplemental Methods for additional details regarding amplification conditions, library preparation, sequencing, and a comprehensive account of analytical approaches.

**Data availability**

Metataxonomics sequence data supporting the conclusions of this manuscript are available via NCBI SRA BioProject Accession PRJNA594611 and on this project’s GitHub repository located at github.com/kdprkr/ConjurersBrew, along with each of the materials needed to reproduce the analysis.

**RESULTS**

**Colon tissue and stool metabolomes of normal weight, overweight and obese adults**

The stool metabolome of healthy adults classified according to BMI as normal weight, overweight or obese had a total of 842 named compounds (Supplemental Table 1). The 842 stool metabolites consisted of 175 amino acids, 26 peptides, 33 carbohydrates, 11 energy, 345 lipids, 46 nucleotides, 47 cofactors and vitamins, and 159 were classified as exogenous and referred to as xenobiotics. There were 98 stool metabolites that significantly differ according to BMI were 22 amino acids, 1 peptide, 8 nucleotides, 2 cofactors and vitamins, 9 xenobiotics and 56 lipids. Principal component analyses (PCA) for the stool metabolome (Supplemental Figure 1A) and hierarchal clustering (Supplemental Figure 1B) did not clearly separate participants by BMI groups. The 504 colon metabolites with known identity and 44 unnamed/unknown compounds from 24 male and female participants are provided

---

Baxter BA et al. Metabolite profile of colon tissue

January 21, 2020 Volume 26 Issue 3
Baxter BA et al. Metabolite profile of colon tissue

in Supplemental Table 2. The colon metabolome contained 93 amino acids, 13 peptides, 35 carbohydrates, 10 metabolites were classified under TCA cycle and oxidative phosphorylation and there were 20 cofactors and vitamins. The largest portion of the colon tissue metabolome were lipids (about 50%, 262 lipid metabolites) that span 40 sub-metabolic pathways. Other notable small molecules from colon were 38 nucleotides and 32 exogenous, xenobiotic metabolites. Fourteen out of twenty-four healthy participants had 1-14 polyps removed during screening colonoscopy. A regression analysis for colon metabolites adjusting for the effect of weight was done, revealing 17 colon metabolites that had lower expression correlated with polyps removed (Supplemental Table 3). Figure 1A, shows 2-arachidonoylglycerol, 3-phosphoglycerate, and 6-phosphogluconate had a lower relative abundance in ascending and descending tissue from participants with polyps removed. Figure 1B-C, shows 1-dihomo-linolenylglycerol, aspartate, and glycerophosphorycholine (GPC) with lower expression in ascending colon tissue, while glutarate (C5-DC), and 2-hydroxyarachidate had lower expression in descending tissue from participants with polyps removed (Figures 1B and C).

Random forest analysis of colon tissue comparing normal weight vs overweight/obese yielded 30 metabolites with a predictive accuracy of 56% for the overweight/obese phenotype (Supplemental Figure 2A). BMI associated colon metabolites were bile acids and cofactors/vitamins (e.g., biliverdin, alpha-tocopherol, and pyridoxate). The predictive accuracy for metabolites in ascending versus descending colon was 73%, and 24 of the top 30 metabolites were classified as lipids (Supplemental Figure 2B). Table 2 further shows the 12 metabolites with statistically significant fold difference identified in right/left colon tissue and in stool by BMI comparisons. Figure 2 shows lipids that are significantly different between weight groups for colon tissue and stool (P < 0.05). The phospholipid, trimethylamine N-oxide (TMAO), was 2.80-fold difference from ascending in obese adults, and 6.23-fold difference from stool in overweight adults when compared to normal weight adults (Figure 2A). Endocannabinoids, linoleoylethanolamide (2.11-fold) and oleoylethanolamide (1.60-fold) difference from ascending in normal weight adults and decrease in stool of obese adults (Figure 2B). Furthermore, the median scaled relative abundance of primary and secondary bile acids (chenodeoxycholate 2.89-fold and 0.41-fold, cholate 0.55-fold, and taurodeoxycholate 1.49-fold) had significant differences by colon location and stool (Figure 2C). The primary bile acid, chenodeoxycholate is 2.89-fold difference from ascending in normal weight and 0.41-fold difference from descending in overweight adults, while 21.80-fold difference in stool of overweight adults when compared to normal weight. Cholate is 0.55-fold difference from obese descending colon and 61.06-fold difference from overweight stool when compared to normal weight (Figure 2C). The secondary bile acid, taurodeoxycholate, had 1.49-fold difference from ascending colon in overweight adults and 9.32-fold difference in stool of overweight adults compared to normal weight (Table 2 and Figure 2C).

BMI differentiates ascending and descending colon lipids

We next utilized metabolomics to distinguish ascending and descending colon tissue. There were 87 metabolites with statistically significant fold differences between ascending vs descending colon by BMI. These included, 46 metabolites in normal weight, 37 metabolites in overweight, and 28 metabolites in obese. Notably, the number of metabolites distinguishing ascending and descending colon decreased as BMI increased. We found that 62% of the metabolites distinguishing ascending and descending colon were lipids. Table 3 shows 54 colon tissue lipids with statistically significant fold difference between ascending and descending colon. In normal weight adults there were 29 colon lipids, 24 of which were fatty acids and lysophospholipid (1.48-fold – 2.16-fold difference) from ascending, and 5 that were from descending colon. Overweight adults had 24 significantly different colon lipids; 11 metabolites from ascending, (8 derived from monoacylglycerols 1.67-fold – 2.61-fold), and 13 metabolites with higher abundance from descending tissue (Table 3). Obese adults had the fewest significant differences in colon lipids between ascending and descending tissue (15 identified metabolites). Table 3 shows 4 metabolites increased in ascending tissue and 11 increased in descending tissue that were primarily fatty acids. Figure 3 shows median scaled relative abundance of right and left colon tissue lipids, including those that are food derived long chain fatty acids and microbiome-products. The long chain fatty acids; palmitate 1.35-fold, arachidate 1.35-fold, and stearate 1.39-fold from ascending tissue in normal weight, and palmitate 0.73-fold, arachidate 0.69-fold, and stearate 0.68-fold from descending tissue in obese adults (Figure 3A). Figure 3B shows microbiome-influenced metabolites that show significant fold difference in colon; 15-HETE from ascending tissue is 1.69-fold in normal weight and 1.93-fold in obese while, 3-hydroxybutyrate is 0.48-fold from descending in normal weight, and 2-
archidonoylglycerol is 1.68-fold from ascending tissue in overweight adults (Figure 3B). This study suggests as BMI increases lipid diversity decrease in the colon and primarily in the ascending colon.

**Ascending and descending colon tissue and stool microbiota composition**

To explore associations of taxonomic groups with ascending colon, descending colon, and stool in a healthy weight adult female, we constructed a compositional PCA biplot from centred log-ratio transformed relative abundances. We observed marked separation across all three sample types at the phylum-, family-, and genus-levels. (Figure 4, Supplementary Table 4). Differences between ascending and descending colon were driven by increased abundance for several taxa in the Firmicutes phylum, including *Anaerostipes*, *Blautia*, *Dorea*, and *Fusicatenibacter* (all members of the *Lachnospiraceae* family), as well as *Streptococcus* and *Romboutsia* (members of the *Streptococcaceae* and *Peptostreptococcaceae* families, respectively). Stool samples were also differentiated by the genus *Bifidobacterium* (a member of the phylum Actinobacteria). Comparisons of the composition between colon samples (ascending versus descending) indicated enrichments for *Bacteroides*, *Ruminiclostridium 9*, *Ruminococcus gnavus*, and *Tyzzerella* in the ascending colon, while the descending colon harbored more *Barnesiella*, *Faecalibacterium*, *Parabacteroides*, *Parasutterella*, and *Roseburia* (Figure 4C and Supplemental Table 4).

**DISCUSSION**

This study demonstrated colon tissue metabolite profile differences between normal weight, overweight and obese adults, and metabolic distinctions between ascending and descending colon within each of the BMI groups. A healthy human colon tissue metabolome had not previously been established across multiple metabolic pathways and revealed 504 known metabolites in both ascending and descending colon locations. Metabolomics has been widely employed for understanding changes that may result from colon metabolism, but the actual metabolite measurements for association with gut health have been from plasma[26], urine[27], stool[29], and from cancerous tissue[30] or other digestive disease conditions[31].

Our findings support that a healthy normal weight colon tissue metabolome involves complex lipid metabolism and that differences in lipid metabolite abundance between the right and left colon is associated with regulation of body weight.
Table 2  Fold-differences of colon and stool metabolites

| Subpathway | Biochemical name | Fold difference colon ascending/descending | Fold difference stool BMI comparisons |
|------------|------------------|------------------------------------------|-------------------------------------|
|            |                  | NW | P value | OW | P value | OB | P value | NW | P value | OB | NW | P value |
| Methionine, Cysteine, SAM and taurine metabolism | N-acetylglut-amine | 1.47 | 0.027 | 1.15 | 0.412 | 1.13 | 0.334 | 1.20 | 0.711 | **3.44** | 0.029 | 0.35 | 0.096 |
| Endocannabinoid | Oleoyl ethanola-mide | 1.6 | 0.038 | 1.06 | 0.790 | 1.55 | 0.109 | 0.23 | 0.261 | 1.94 | 0.174 | **0.12** | **0.026** |
| | Linoleoyl ethanola-mide | **2.11** | **0.005** | 1.26 | 0.351 | 1.52 | 0.171 | 0.21 | 0.172 | 2.49 | 0.146 | **0.08** | **0.012** |
| Phospholipid metabolism | Trimethyl-tamine N-oxide | 0.92 | 0.832 | 1.02 | 0.969 | **2.8** | **0.049** | 1.47 | 0.494 | **6.23** | **0.025** | 0.24 | 0.149 |
| | 1-palmitoyl-2-oleoyl-GPE (16/0/18:1) | 0.77 | 0.145 | 0.66 | **0.029** | 0.7 | 0.113 | **2.63** | **0.044** | 2.57 | 0.244 | 1.02 | 0.322 |
| Lyso phospholipid | 2-palmitoyl-GPC (16:0) | **1.52** | **0.019** | 1.18 | 0.317 | 0.93 | 0.709 | 0.84 | 0.667 | 2.81 | 0.061 | **0.30** | **0.039** |
| | 1-linoleoyl-GPC (18:2) | **1.55** | **0.030** | 1.26 | 0.239 | 1.05 | 0.819 | 1.25 | 0.335 | **3.45** | **0.001** | **0.36** | **0.010** |
| Primary bile acid metabolism | Cholate | 1.12 | 0.612 | 0.84 | **0.447** | 0.55 | **0.041** | 3.13 | 0.512 | **61.06** | **0.019** | 0.05 | 0.114 |
| | Chenodeoxychola-te | **2.89** | **0.049** | 0.41 | 0.094 | 0.9 | 0.872 | 0.76 | 0.697 | **21.80** | **0.005** | 0.03 | **0.004** |
| Secondary bile acid metabolism | Taurodeoxycholate | 1.13 | 0.482 | 1.49 | **0.027** | 0.78 | 0.249 | 0.43 | 0.434 | 9.32 | 0.080 | **0.05** | **0.024** |
| Pyrimidine metabolism, cytidine containing | Cytidine | **1.93** | **0.036** | 1.46 | 0.216 | 1.12 | 0.748 | 1.25 | 0.469 | **2.06** | **0.047** | 0.61 | 0.249 |

1Not officially confirmed, but confident. Values presented are fold-change of the mean relative abundance within ascending versus descending colon tissue and BMI comparisons from stool. Bold indicates P value < 0.05. NW: Normal weight; OW: overweight; OB: Obese; BMI: Body mass index.

Differences were identified for right and left colon metabolites from the endocannabinoid pathway that may signify control over energy metabolism, which regulates appetite, lipolysis, and energy expenditure. The endocannabinoid pathway is implicated in both homeostatic and hedonic food intakes that result in increased hunger. Specific endocannabinoids, such as the monounsaturated oleoylethanolamide, saturated palmitoylethanolamide and polyunsaturated linoleoylethanolamide showed higher relative abundance in normal weight adults from ascending colon compared to descending colon, and relative higher abundance from stool in overweight adult compared to normal weight. These lipids are also important for regulating metabolism in immune and neuronal cells. Oleoylethanolamide levels in the mucosal layer of the proximal small intestine was shown to increase with nutrient availability and may be another factor in the
| Sub pathway                          | Biochemical name            | Fold difference ascending/descending |
|-------------------------------------|-----------------------------|-------------------------------------|
|                                     |                             | NW  | P value | OW  | P value | OB  | P value |
| Long chain fatty acids              | Palmitate (16:0)            | 1.3 | 0.02    | 1.0 | 0.75    | 0.7 | 0.04    |
|                                     | Margarate (17:0)            | 1.2 | 0.13    | 0.8 | 0.33    | 0.7 | 0.03    |
|                                     | Stearate (18:0)             | 1.3 | 0.01    | 0.9 | 0.61    | 0.6 | 0.01    |
|                                     | Oleate/vaccenate (18:1)     | 1.5 | 0.04    | 1.2 | 0.36    | 0.9 | 0.80    |
|                                     | Nonadecanoate (19:0)        | 1.1 | 0.29    | 0.8 | 0.26    | 0.6 | 0.01    |
|                                     | Arachidate (20:0)           | 1.3 | 0.02    | 0.9 | 0.56    | 0.6 | 0.02    |
|                                     | Eicosenoate (20:1)          | 1.4 | 0.04    | 1.1 | 0.56    | 1.0 | 0.88    |
|                                     | Erucate (22:1n9)            | 1.5 | 0.03    | 1.0 | 0.81    | 1.1 | 0.47    |
| Polyunsaturated fatty acid          | Dihomo-linolenate (20:3n3 or n6) | 1.5 | 0.04 | 1.2 | 0.28 | 1.1 | 0.56 |
|                                     | Dihomo-linoleate (20:2n6)   | 1.6 | 0.01    | 1.1 | 0.41    | 1.2 | 0.46    |
| Fatty acid, dicarboxylate           | Dodecanedioate (12:2)       | 0.9 | 0.64    | 0.8 | 0.26    | 0.7 | 0.03    |
| Ketone bodies                       | 3-hydroxybutyrate (BHBA)    | 0.4 | 0.00    | 0.9 | 0.90    | 1.0 | 0.82    |
| Fatty acid, metabolism (Acyl choline) | Linoleoylethanolamine³     | 1.2 | 0.34    | 1.1 | 0.62    | 2.0 | 0.02    |
| Fatty acid, monohydroxy             | 2-hydroxystearate           | 1.3 | 0.04    | 0.9 | 0.67    | 0.7 | 0.13    |
| Eicosanoid                          | 15-HETE                     | 1.6 | 0.04    | 1.1 | 0.51    | 1.9 | 0.03    |
| Endocannabinoid                     | Oleoylethanolamide          | 1.6 | 0.03    | 2.2 | 0.79    | 1.5 | 0.10    |
|                                     | Palmitoyl ethanolamide      | 1.3 | 0.02    | 1.0 | 0.56    | 1.1 | 0.42    |
|                                     | Linoleoyl ethanolamide      | 2.1 | 0.00    | 1.2 | 0.35    | 1.5 | 0.17    |
| Phosphatidylethanolamine            | 1-stearoyl-2-oleoyl-GPE (18:0/18:1) | 0.8 | 0.28 | 0.6 | 0.01 | 0.7 | 0.15 |
|                                     | 1-stearoyl-2-linoleoyl-GPE (18:0/18:2) | 0.9 | 0.87 | 0.6 | 0.04 | 0.6 | 0.09 |
|                                     | 1,2-dioleoyl-GPE (18:1/18:1) | 0.6 | 0.07    | 0.6 | 0.03    | 0.7 | 0.19    |
|                                     | 1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) | 0.6 | 0.01 | 0.7 | 0.08 | 0.4 | 0.00 |
| Lysosphospholipid                   | 1-palmitoleoyl-GPC (16:1)   | 1.5 | 0.03    | 1.3 | 0.20    | 1.2 | 0.33    |
|                                     | 1-linoleoyl-GPC (18:2)      | 1.6 | 0.00    | 1.5 | 0.01    | 1.4 | 0.08    |
|                                     | 1-arachidonoyl-GPC (20:4n6) | 1.74 | 0.035 | 1.55 | 0.092 | 1.39 | 0.285 |
|                                     | 1-linoleoyl-GPC (18:2)³     | 1.8 | 0.00    | 1.4 | 0.07    | 1.2 | 0.31    |
|                                     |                             | 9.2 | 2.0     | 1.7 | 6.0     | 4.0 | 5.0     |

³ indicates significant difference.
| Metabolite                                      | Fold-change | Relative abundance | Relative abundance | Relative abundance |
|-----------------------------------------------|-------------|--------------------|--------------------|--------------------|
| 1-palmitoyl-GPG (16:0)                         | 2.1         | 0.00               | 1.3                | 0.18               | 0.8                | 0.51               |
| 1-stearoyl-GPG (18:0)                          | 2.1         | 0.00               | 1.3                | 0.16               | 0.8                | 0.66               |
| 1-oleoyl-GPG (18:1)                            | 1.6         | 0.01               | 1.0                | 0.66               | 1.1                | 0.47               |
| 1-palmitoyl-GPI (16:0)                         | 1.5         | 0.04               | 1.1                | 0.55               | 0.7                | 0.31               |
| 1-stearoyl-GPI (18:0)                          | 1.4         | 0.03               | 1.0                | 0.66               | 0.8                | 0.50               |
| 1-oleoyl-GPI (18:1)                            | 1.6         | 0.02               | 1.2                | 0.24               | 0.9                | 0.81               |
| 1-linoleoyl-GPI (18:2)                         | 1.4         | 0.01               | 1.1                | 0.48               | 1.2                | 0.22               |
| Plasmalogen                                    |             |                    |                    |                    |                    |                    |
| 1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1)| 0.7         | 0.08               | 0.6                | 0.02               | 0.6                | 0.13               |
| 1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)| 0.7         | 0.10               | 0.6                | 0.01               | 0.7                | 0.16               |
| 1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1)| 0.7         | 0.23               | 0.6                | 0.03               | 0.7                | 0.31               |
| Monoacylglycerol                               |             |                    |                    |                    |                    |                    |
| 1-palmitoylglycerol (16:0)                     | 1.3         | 0.25               | 2.6                | 0.00               | 1.2                | 0.53               |
| 1-palmitoleoylglycerol (16:1)                  | 1.6         | 0.09               | 2.2                | 0.00               | 1.1                | 0.62               |
| 1-oleoylglycerol (18:1)                        | 1.6         | 0.20               | 2.2                | 0.03               | 0.7                | 0.50               |
| 1-linolenoylglycerol (18:3)                    | 1.5         | 0.07               | 2.0                | 0.00               | 1.0                | 0.82               |
| 1-dihomo-linolenoylglycerol (20:3)             | 1.5         | 0.25               | 2.2                | 0.04               | 0.7                | 0.57               |
| 1-arachidonoylglycerol (20:4)                  | 1.5         | 0.21               | 2.3                | 0.01               | 1.1                | 0.78               |
| 2-palmitoleoylglycerol (16:1)                  | 1.3         | 0.25               | 1.7                | 0.03               | 0.9                | 0.89               |
| 2-arachidonoylglycerol (20:4)                  | 1.3         | 0.25               | 1.6                | 0.03               | 0.9                | 0.75               |
| Diacylglycerol                                 |             |                    |                    |                    |                    |                    |
| Linoleoyl-linolenoylglycerol (18:2/18:3) (2)   | 1.3         | 0.51               | 1.6                | 0.29               | 3.3                | 0.03               |
| Ceramides                                      |             |                    |                    |                    |                    |                    |
| N-palmitoyl-sphingosine (d18:1/16:0)           | 0.9         | 0.73               | 0.6                | 0.00               | 0.7                | 0.04               |
| N-stearoyl-sphingosine (d18:1/16:0)            | 1.0         | 0.57               | 0.7                | 0.03               | 0.8                | 0.33               |
| N-palmitoyl-heptadecasphingosine (d17:1/16:0)  | 0.9         | 0.95               | 0.7                | 0.04               | 0.8                | 0.20               |
| Hexosylceramides (HCER)                        |             |                    |                    |                    |                    |                    |
| Glycosyl-N-palmitoyl-sphingosine (d18:1/16:0)  | 0.7         | 0.04               | 0.6                | 0.00               | 0.6                | 0.02               |
| Primary bile acid                              |             |                    |                    |                    |                    |                    |
| Glycochenodeoxycholate                         | 0.9         | 0.75               | 1.8                | 0.00               | 0.8                | 0.54               |
| Taurochenodeoxycholate                         | 1.0         | 0.98               | 1.6                | 0.45               | 0.8                | 0.1                |
| Secondary bile acid                            |             |                    |                    |                    |                    |                    |
| Glycolithocholate sulfate                      | 0.9         | 0.70               | 1.4                | 0.01               | 1.1                | 1                  |
| Deoxycholate                                   | 0.9         | 0.79               | 0.6                | 0.12               | 0.7                | 0.00               |

1Not officially confirmed, but confident. Values presented are fold-difference of the mean relative abundance between ascending/descending colon, by
regulation of satiety. Palmitoylethanolamide has supportive roles for reducing inflammation and eliciting neuroprotective effects, while linoleoylethanolamide has reported anti-inflammatory functions.

Bile acids are important signaling molecules which contribute to regulation of whole-body glucose, lipid metabolism, and body weight. Primary and secondary bile acids were also identified for distinctions in abundance by colon location and from stool between overweight/obese and normal weight adults. Primary bile acids produced in the liver and increased bile acids in colon tissue may indicate altered reabsorption of bile acid by the liver and that results in subsequent alteration to metabolism by intestinal microbiota. Primary bile acids, cholic acid and chenodeoxycholic acid, are derived from cholesterol by an enzymatic reaction occurring mainly in the liver. Chenodeoxycholate has shown to increase colonic transit and improves bowel function. Dietary cholic acid supplementation in rats caused a significant increase in colon tumors. Interestingly, this study showed that primary bile acids; glycocholate, glycochenodeoxycholate, and taurochenodeoxycholate had 1.26-fold - 1.86-fold difference in overweight colon and merit attention as a mechanism with alongside other lipid classes to increase cancer risk in people. Concentrations of bile salts was shown to be higher in the proximal colon and bile-acid profiles were hypothesized to increase the risk of proximal cancer.

Population-based studies have shown that individuals who consume high-fat and high-beef foods display elevated levels of fecal secondary bile acids, as do patients diagnosed with colon carcinomas. Secondary bile acid, taurodeoxycholate are generated from primary bile acids and were shown to be increased in obese children plasma when compared to insulin-resistance when compared to resistant counterparts, unveiling the influence of the gut microbiota on the host metabolism. Glycochenodeoxycholate a secondary bile acid produced by microbial flora in the large intestine was associated with colorectal cancer in women, and high levels of deoxycholate in blood, bile feces, and mucosa were increased in colorectal cancer. This study showed elevated glycochenodeoxycholate from descending colon in overweight adults, and elevated deoxycholate from descending colon in obese adults. Impaired bile acid signaling and dysbiosis may contribute to type 2 diabetes and other metabolic disease associated with obesity and colorectal cancer risk. This study had limitations in the total sample size for each BMI and did not control for different dietary intake patterns. The lack of gender balance in each BMI subgroup was also a potential source of bias for sex-based differences that may exist in colon tissue metabolite profiles. Future studies that control these variables merit attention because the colon tissue metabolite signatures that emerged herein did demonstrate metabolic relevance to the high risk of overweight and obesity in the progression of proximal and distal colon cancers.

Colonic TMAO abundance in obesity was a major finding from this study with respect to risk for cancer and supports a role for phospholipids from choline metabolism. TMAO was identified herein for increased abundance in ascending colon of obese adults and in stool of overweight adults. Deng et al. showed increased plasma levels of TMAO in patients with right sided colon cancer when compared to left sided colon cancer patients. High urine concentration of TMAO also directly correlated to the consumption of a high meat containing diet and higher total milk and dairy consumption in plasma. The increased levels in serum and urine were also shown to be associated with predisposition to impaired glucose homeostasis in high fat diet-fed mice. Links between colorectal cancer and TMAO was detected in a genome-wide systems analysis and in the development of colorectal cancer. Our findings also revealed microbiome-influenced metabolites in the colon tissue that were not in the stool, such as the ketone body, 3-hydroxybutyrate, an eicosanoid; 15-Hydroxyeicosatetraenoic acid (15-HETE), and the monoacylglycerol; 2-arachidonoylglycerol. Ketone bodies are strongly affected by obesity-related metabolic disorders and are utilized in the body as an energy source. In visceral adipose tissue from obese subjects, 15-HETE was higher than in healthy subjects. These aforementioned metabolic changes support the differences in microbiota between stool and colon and between colon locations (ascending vs descending). Right and left colon microbiota analysis for differences in healthy adults has been limited. We observed an increased abundance of Bacteroidetes in the ascending colon and Proteobacteria in the descending colon that were consistent with Flynn et al. Given that stool did not recapitulate the composition of the colonic mucosa-associated microbiota and metabolites, additional investigations with larger cohorts of each BMI group is warranted that will assess impacts of intervention strategies to reduce
disease risk.

Fatty acids were also statistically supported in abundance by right and left location, and alongside BMI. Food-derived long chain fatty acids are found in dairy fat, coconut oil, palm kernel oil, peanut oil and vegetable oils. Monounsaturated long-chain fats such as oleic acid, and palmitoleic acid are found in animal fats, olive, canola and safflower oil. Oleic acid enhances insulin action and inhibits glucose production\(^\text{[51]}\), but also demonstrates cardiovascular benefits when it replaces heart-damaging saturated fat\(^\text{[52]}\). Palmitic acid is the first fatty acid produced during fatty acid synthesis, and is the precursor to longer fatty acids, while excess carbohydrates in the body may also be converted to palmitic acid. This analysis revealed major differences in long chain fatty acids as relevant to normal weight ascending colon and were also significantly different in the opposite direction of obese adults, namely increased in descending colon. Polysaturated long chain fats include linoleic acid, alpha-linolenic acid (seeds and nuts), arachidonic acid (meat, eggs, and algae) and eicosapentaenoic acid (fish oil)\(^\text{[53]}\). Margarate, also known as heptadecanoic acid is a biomarker of long-term milk fat intake\(^\text{[54]}\), and was elevated in the obese adults for descending colon. Stearate fed to mice showed 70% reduction of visceral fat\(^\text{[55]}\), and reduced metastasis tumor burden in a breast cancer mouse model\(^\text{[56]}\). Arachidate is necessary for the function of all cells, especially in the nervous system, skeletal muscle and immune systems\(^\text{[57]}\).

In conclusion, our study identified important metabolic differences between the right and left colon tissue of healthy adults and highlighted a wide range of lipids from normal weight, overweight and obese adults. The magnitude and abundance of a metabolite difference between ascending and descending colon tissue has not been previously evaluated and warrants further investigation for screening risk of proximal versus distal colon cancers.
Figure 3  Fold-differences of ascending vs descending lipid metabolites in normal weight, overweight and obese adults. A: Long chain fatty acids; palmitate, arachidate, and stearate; B: Microbiome influenced metabolites; 15-HETE, 3-hydroxybutyrate (BHBA), and 2-arachidonoylglycerol. Open circles represent ascending colon, closed circles represent descending colon ($^aP < 0.05$, $^bP < 0.01$).
Figure 4 Composition of microbiota from stool, ascending and descending colon in a healthy, normal weight adult. Left side shows principal components analysis biplots of centred log-ratio transformed relative abundances at the phylum; A: Family; B: Genus; C: Levels. Lines with arrows represent individual taxa. Right side shows relative abundance bar charts for the most abundant taxa at the respective taxonomic level across stool and colon location sample types.

ARTICLE HIGHLIGHTS

Research background
Obesity is a risk factor for colorectal cancer, yet metabolic distinctions between healthy right and left colon tissue, before cancer is diagnosed, remains largely unknown.

Research motivation
Colon cancer of the ascending colon has a poorer prognosis and survival when compared to colon cancer on the descending colon. Stool metabolite composition does not accurately reflect proximal/ascending/right sided colon. Development of healthy colon tissue small molecule signatures for ascending and descending colon will aid in our understanding of how to improve gut metabolism and may help prevent or mitigate colorectal cancer risk.

Research objectives
This study compared right-ascending and left-descending colon tissue metabolomes and sought to identify differences from the stool metabolome in normal weight, overweight, and obese adults.

Research methods
Global, non-targeted metabolomics was applied to assess right-ascending and left-descending colon tissue collected from healthy adults undergoing screening colonoscopies to test the
hypothesis that body mass index (BMI) differentially impacts colon tissue metabolite profiles. The colon tissue and stool metabolome of healthy adults was analyzed for metabolite signatures and metabolic pathway networks implicated in progression and prevention of colorectal cancer.

**Research results**

This is the first report using metabolomics to compare the right-ascending vs left-descending colon tissue of healthy adults. Our findings show that BMI was associated with metabolite profile differences between the ascending and descending colon. Disturbances in multiple metabolic pathways of the right and left colon from being overweight/obese may have important implications for increasing colorectal cancer risk.

**Research conclusions**

There were metabolite profile differences between right-ascending and left-descending colon tissue in healthy adults receiving routine, screening colonoscopies. BMI impacts the number, type and magnitude of metabolite differences between the ascending and descending colon. Colon lipids and other metabolites in obese and overweight adults were distinguished from normal weight participants and associated with gut inflammation, nutrient absorption, and products of microbiota metabolism.

**Research perspectives**

Right and left colon tissue metabolites that differ in relative abundance between normal weight, overweight, obese adults may be sensitive biomarkers for colon cancer risk. Diet and lifestyle influence right and left sided colon tissue metabolite composition that shape inflammation and cancer risk in overweight and obese adults. Development of healthy colon tissue small molecule signatures for ascending and descending colon will aid in our understanding of how to improve gut metabolism and may help prevent or mitigate colorectal cancer risk.

**ACKNOWLEDGEMENTS**

We would like to thank the study participants, Erica Borresen, Renee Oppel and Luke Schwerdtfeger for assisting with recruitment, consent, and sample procurement from participating gastroenterology/endoscopy clinics and transporting samples to Colorado State University. We also thank Dr. Daniel Hampton, Dr. Rebecca Dunphy and Dr. Nicole Kershner for tissue biopsy collections from screening colonoscopies.

**REFERENCES**

1. Zeng H, Lazarova DL. Obesity-related colon cancer: dietary factors and their mechanisms of anticancer action. *Clin Exp Pharmacol Physiol* 2012; 39: 161-167 [PMID: 22418088 DOI: 10.1111/j.1440-1681.2011.05518.x]

2. Tarasuk A, Mosinska P, Fichna J. The mechanisms linking obesity to colon cancer: An overview. *Obes Res Clin Pract* 2018; 12: 251-259 [PMID: 29482365 DOI: 10.1016/j.orcp.2018.01.005]

3. Lee GH, Maltezis G, Askari A, Bernardo D, Al-Hassani HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. *Eur J Surg Oncol* 2015; 41: 300-308 [PMID: 25468456 DOI: 10.1016/j.ejso.2014.11.001]

4. Giovannucci E, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk of colorectal adenoma in women (United States). *Cancer Causes Control* 1996; 7: 253-263 [PMID: 8740738 DOI: 10.1007/bf00051301]

5. Song M, Hu FB, Spiegelman D, Chan AT, Wu K, Ogino S, Fuchs CS, Willett WC, Giovannucci EL. Adulthood Weight Change and Risk of Colorectal Cancer in the Nurses’ Health Study and Health Professionals Follow-up Study. *Cancer Prev Res (Phila)* 2015; 8: 620-627 [PMID: 25930050 DOI: 10.1158/1940-6207.CAPR-15-0061]

6. Moore LI, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC, Keerger BE. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. *Int J Obes Relat Metab Disord* 2004; 28: 559-567 [PMID: 14770200 DOI: 10.1038/sj.ijo.0802606]

7. Brown DG, Rao S, Weir TL, O’Malia J, Bazan M, Brown JR. Metabolomic and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. *Cancer Metab* 2016; 4: 11 [PMID: 27275383 DOI: 10.1186/s40170-016-0151-v]

8. Hullar MA, Fu BC. Diet, the gut microbiome, and epigenetics. *Cancer* 2014; 20: 170-175 [PMID: 24855003 DOI: 10.1097/PPO.0000000000000053]

9. Weir TL, Manter DK, Shefflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. *PLoS One* 2013; 8: e70803 [PMID: 23940645 DOI: 10.1371/journal.pone.0070803]

10. Wang CB, Shahjehan F, Merchea A, Li Z, Bekaii-Saab TS, Grotehoy A, Coltbaseanu DT, Kasi PM. Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. *Front Oncol* 2019; 9: 76 [PMID: 30838175 DOI: 10.3389/fonc.2019.00076]

11. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Abuja N. Is there a difference in survival between right- versus left-sided colon cancers? *Ann Surg Oncol* 2008; 15: 2388-2394 [PMID: 18622647 DOI: 10.1245/s10434-008-0015-y]

12. Lim DR, Kuk JK, Kim T, Shin EJ. Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? *Medicine (Baltimore)* 2017; 96: e8241 [PMID: 29049212 DOI: 10.1097/MD.00000000000008241]

Gonzalez EC, Roetzelheim RG, Ferrante JM, Campbell R. Predictors of proximal vs. distal colorectal...
Baxter BA et al. Metabolite profile of colon tissue

13 cancers. *Dis Colon Rectum* 2001; 44: 251-258 [PMID: 11227943 DOI: 10.1007/bf02234301]

14 Bernstein EM, Song M, Zhang X, Pan A, Wang M, Fuchs CS, Le N, Chan AT, Willett WC, Ogino S, Giovannucci EL, Wu K. Processed and Unprocessed Red Meat and Risk of Colorectal Cancer: Analysis by Tumor Location and Modification by Time. *Plas One* 2015; 10: e0135959 [PMID: 26385323 DOI: 10.1371/journal.pone.0135959]

15 Kim S, Kim J, Yun EJ, Kim KH. Food metabolomics: from farm to human. *Curr Opin Biotechnol* 2016; 37: 16-23 [PMID: 26426939 DOI: 10.1016/j.copbio.2015.09.004]

16 Hale VI, Jerald P, Mundy M, Yao J, Keeney G, Scott N, Cheek EH, Davidson J, Greene M, Martinez C, Lehman J, Petry C, Reed E, Lyke K, White BA, Dyer C, Resende-Antonio O, Giancana J, Dutta T, Petterson XM, Boardman L, Larson D, Nelson H, Chia N. Synthesis of multi-omic data and community metabolite models reveals insights into the role of hydrogen sulfide in colon cancer. *Methods* 2018; 149: 59-68 [PMID: 29704655 DOI: 10.1016/j.meth.2018.04.024]

17 Montrose DC, Zhou XK, Kopelowich L, Yantiss RK, Karoly ED, Subbarajamah K, Dannenberg AP. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. *Cancer Prev Res (Phila)* 2012; 5: 1358-1367 [PMID: 22961778 DOI: 10.1158/1940-6207.CAPR-12-0160]

18 Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. *Nat Rev Microbiol* 2016; 14: 20-32 [PMID: 26498985 DOI: 10.1038/nrmicro3552]

19 Flynn J, Ruffin MT 4th, Turgeon DK, Schluss PD. Spatial Distribution of the Native Colon Microbiota in Healthy Adults. *Cancer Prev Res (Phila)* 2018; 11: 393-402 [PMID: 29636352 DOI: 10.1158/1940-6207.Capr-17-0370]

20 Ward JH. Hierarchical Grouping to Optimize an Objective Function. *J Am Stat Assoc* 1963; 58: 234-246 [DOI: 10.1080/01621459.1963.10500845]

21 Breiman L. Random Forests. *Mach Learn* 2001; 45: 5-32 [DOI: 10.1023/a:1010334043424]

22 Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghlith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Bristlavan CJ, Brown CT, Callahan BJ, Caraballo-Rodriguez AM, Chase J, Cope KE, Da Silva R, Diener C, Dorresteen PC, Douglas GM, Durali DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquet J, Gauglitz JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hemmings S, Holm HE, Janssen S, Jarmusch AK, Jiang L, Kacifler BD, Kang KB, Kenet R, Kedin T, Knights D, Koester I, Koscielko T, Kreps J, Langille MG, Lee J, Lee Y, Liu YX, Loffeld E, Lozupone C, Maher M, Marotz C, Martin BD, McDiver MJ, Melnik AV, Metcalfe JL, Morgan SC, Morton JT, Naimay AT, Navas-Molina JM, Nothias LF, Orchanian SB, Pearson T, Peoples SL, Peters D, Preuss ML, Pruesse E, Rasenbussen LB, Rivers A, Robinson MS, S2nd, Rosado SF, Segata N, Seshadri V, Song SJ, Spear JR, Swafford AD, Thompson LR, Torres PJ, Trinh P, Tripathi A, Turnbaugh PJ, U-Hassan S, van de Hoof J2, Vargas F, Vázquez-Baéza Y, Vogtmann E, von Hippel M, Walters W, Wang Y, Wang M, Warren J, Weber KC, Williamson CHD, Willis AD, Xu ZZ, Zanevedel JR, Zhang Y, Zuo Q, Knight R, Caporaso JG. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nature* 2019; 578: 852-857 [PMID: 31341288 DOI: 10.1038/s41586-019-1358-2]

23 Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat Methods* 2016; 13: 581-583 [PMID: 27244074 DOI: 10.1038/nmeth.3869]

24 R-Core-Team. R: A language and environment for statistical computing. 3.5.2 ed. Vienna: R Foundation for Statistical Computing, 2019.

25 Gloor GB, Macklaim JM, Pawlowski-Glahn V, Egozcue JJ. Microbiome Datasets Are Compositional: And This Is Not Optional. *Front Microbiol* 2017; 8: 2224 [PMID: 29187837 DOI: 10.3389/fmicb.2017.02224]

26 Deng K, Han P, Song W, Wang Z, Zhang F, Xie H, Zhao W, Xu H, Cai Y, Cui BB, Li K. Plasma metabolic profiling distinguishes right-sided from left-sided colon cancer. *Clin Chim Acta* 2018; 487: 357-362 [PMID: 30296444 DOI: 10.1016/j.cca.2018.10.010]

27 Wang H, Tao V, Wong C, Sadowski D, Fedorak RN. Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps. *Clin Transl Gastroenterol* 2014; 5: e54 [PMID: 24646906 DOI: 10.1038/ctg.2014.65]

28 Griffen JL, Shockcor JP. Metabolic profiles of cancer cells. *Nat Rev Cancer* 2004; 4: 551-561 [PMID: 15229480 DOI: 10.1038/nrc1390]

29 Socciwe EA, Allaman MM, Brown CT, Motley AK, Horst SN, Williams CS, Koyama T, Zhao Z, Adams DW, Beaulieu DB, Schwartz DA, Wilson KT, Coburn LA. Alterations in Lipid, Amino Acid, and Energy Metabolism of Cancer Cells. *Cancer Cell* 2015; 28: 1518-1528 [PMID: 26426959 DOI: 10.1016/j.cccr.2015.09.001]

30 Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. *Int J Obes (Lond)* 2006; 30 Suppl 1: S7-S12 [PMID: 16570107 DOI: 10.1038/sj.jibo.0803271]

31 Fu J, Astardia G, Gaetani S, Kim J, Cravatt BF, Mackie K, Piomelli D. Food intake regulates oleoylthanolamide formation and degradation in the proximal small intestine. *J Biol Chem* 2007; 282: 1518-1528 [PMID: 17121838 DOI: 10.1074/jbc.M607890200]

32 Andersen SR, Bing J, Hansen RM, Biering-Sorensen F, Johannessen IL, Hagen EM, Rice AS, Nielsen JF, Bach FW, Finnerup NB. Ultramicronized palmitoleoylthanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. *Pain* 2016; 157: 2097-2103 [PMID: 27272691 DOI: 10.1097/j.pain.0000000000002623]

33 Ishida T, Nishimura S, Tanahashi T, Yamazaki A, Yamazaki A, Akashi T, Miki I, Kondo Y, Inoue J, Kawauchi S, Azuma T, Yoshida M, Mizuno S. Linoleoyl ethanolamide reduces lipopolysaccharide-induced inflammation in macrophages and ameliorates 2,4-dinitrofluorobenzene-induced contact dermatitis in mice. *Eur J Pharmacol* 2013; 699: 6-13 [PMID: 23201070 DOI: 10.1016/j.ejphar.2012.11.010]

34 Hasenour CM, Ridley DE, Hughey CC, James FD, Donahue EP, Shearer J, Violett B, Foretz M, Wasserman DH, 5-Aminomimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo. *J Biol Chem* 2014; 289: 5950-5959 [PMID: 24405081 DOI: 10.1074/jbc.M113.528232]

35 Li T, Chuang JY. Bile acids as metabolic regulators. *Curr Opin Gastroenterol* 2015; 31: 159-165 [PMID: 26385323 DOI: 10.1097/MOG.0000000000000244]
Baxter BA et al. Metabolite profile of colon tissue

25584736 DOI: 10.1097/MOG.0000000000001546

37 Ajouz H, Mukherji D, Shamseddine A. Secondary bile acids: an underrecognized cause of colon cancer. *World J Surg Oncol* 2014; 12: 164 [PMID: 24884764 DOI: 10.1186/1477-7819-12-164]

38 Rao AS, Wora BS, Camilleri M, Odunsi-Shyanbade ST, McKinzie S, Ryko M, Burton D, Carlson P, Lamsam J, Singh R, Zinsmeister AR. Cholenoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. *Gastroenterology* 2010; 139: 1549-1558, 1558.e1 [PMID: 20691689 DOI: 10.1053/j.gastro.2010.07.052]

39 McSherry CK, Cohen BI, Bokkenheuser VD, Mosbach EH, Winter J, Matoba N, Scholes J. Effects of calcium and bile acid feeding on colon tumors in the rat. *Cancer Res* 1989; 49: 6039-6043 [PMID: 2790818]

40 Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. *J Surg Oncol* 2004; 88: 261-266 [PMID: 15565587 DOI: 10.1002/jso.20156]

41 Nagengast FM, Gruben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. *Eur J Cancer* 1995; 31A: 1067-1070 [PMID: 7576993 DOI: 10.1016/0959-8049(95)00216-6]

42 Mastrangelo A, Martos-Moreno GÁ, Garcia A, Barrios V, Rupérez FJ, Chowen JA, Barbá C, Argente J. Insulin resistance in prepubertal obese children correlates with sex-dependent early onset metabolic alterations. *Int J Obes (Lond)* 2016; 40: 1494-1502 [PMID: 27163744 DOI: 10.1038/ijo.2016.92]

43 Cross AJ, Moore SC, Boca S, Huang WY, Xiong X, Stolzenberg-Solomon R, Sinha R, Sampson JN. A prospective study of serum metabolites and colorectal cancer risk. *Cancer* 2014; 120: 3049-3057 [PMID: 24894841 DOI: 10.1002/cncr.28799]

44 Shapiro H, Koledziejczyk AA, Halstuch D, Elinav E. Bile acids in glucose metabolism in health and disease. *J Exp Med* 2018; 215: 383-396 [PMID: 29393443 DOI: 10.1084/jem.20171965]

45 Stella C, Beckwith-Hall B, Cloarec O, Holmes E, Lindon JC, Powell J, van der Ouderaa F, Bingham S, Cross AJ, Nicholson JK. Susceptibility of human metabolic phenotypes to dietary modulation. *J Proteome Res* 2006; 5: 2780-2788 [PMID: 17022649 DOI: 10.1021/pr060265y]

46 Rohrmann S, Linseisen J, Allenspach M, von Eckardstein A, Müller D. Plasma Concentrations of Trimethylamine-N-oxide Are Directly Associated with Dairy Food Consumption and Low-Grade Inflammation in a German Adult Population. *J Nutr* 2016; 146: 283-289 [PMID: 26674761 DOI: 10.3945/jn.115.220103]

47 Gao X, Liu X, Xu J, Xue C, Xue Y, Wang Y. Dietary trimethylamine-N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. *J Biosci Bioeng* 2014; 118: 476-481 [PMID: 24721123 DOI: 10.1016/j.biosc.2014.03.001]

48 Xu R, Wang Q, Li L. A genome-wide systems analysis reveals strong link between colorectal cancer and trimethylamine-N-oxide (TMAO), a gut microbial metabolite of dietary meat and fat. *BMC Genomics* 2015; 16 Suppl 7: S4 [PMID: 26100814 DOI: 10.1186/1471-2164-16-s7-s4]

49 Giesbertz P, Padberg I, Rein D, Ecker J, Höffe AS, Spanier B, Daniel H. Metabolic profiling in plasma and tissues of ob/db and db/db mice identifies novel markers of obesity and type 2 diabetes. *Diabetologia* 2015; 58: 2133-2143 [PMID: 26058053 DOI: 10.1007/s00125-015-365x-y]

50 Candi E, Tessauro M, Cardillo C, Lena AM, Schinzari F, Rovella V, Amnicchiarico-Petruzzelli M, Di Daniele N, Melino G. Metabolic profiling of visceral adipose tissue from obese subjects with or without metabolic syndrome. *Biochem J* 2018; 475: 1019-1035 [PMID: 29437994 DOI: 10.1042/bcj20170601]

51 Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L. Central administration of oleic acid inhibits glucose production and food intake. *Diabetes* 2002; 51: 271-275 [PMID: 11812732 DOI: 10.2337/diabetes.51.2.271]

52 Voelker R. Oleic Acid Can Make Heart Claim Without Hard Evidence. *JAMA* 2019; 321: 23 [PMID: 30620355 DOI: 10.1001/jama.2018.19747]

53 Kingsbury KJ, Paul S, Crossley A, Morgan DM. The fatty acid composition of human depot fat. *Biochem J* 1961; 78: 541-550 [PMID: 13756126 DOI: 10.1042/bj0780541]

54 Wolk A, Vessby B, Ljung H, Barrefors P. Evaluation of a biological marker of dairy fat intake. *Am J Clin Nutr* 1998; 68: 291-297 [PMID: 9701185 DOI: 10.1093/ajcn/68.2.291]

55 Shen MC, Zhao X, Siegal GP, Desmond R, Hardy RW. Dietary stearic acid leads to a reduction of visceral adipose tissue in athymic nude mice. *PLoS One* 2014; 9: e104083 [PMID: 25222131 DOI: 10.1371/journal.pone.0104083]

56 Evans LM, Toline EC, Desmond R, Siegal GP, Hashim AI, Hardy RW. Dietary stearate reduces human breast cancer metastasis burden in athymic nude mice. *Clin Exp Metastasis* 2009; 26: 415-424 [PMID: 19267249 DOI: 10.1007/s10487-009-9239-3]

57 Tallima H, El Ridi R. Arachidonic acid: Physiological roles and potential health benefits - A review. *J Adv Res* 2018; 11: 33-41 [PMID: 30034874 DOI: 10.1016/j.jare.2017.11.004]
